Rise Advisors’s Pacific Biosciences PACB Stock Holding History

Rise Advisors’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-424	Closed	-$543	–	1046
2025 Q3	$543	Hold	424	–	–	﹤0.01%	1394
2025 Q2	$526	Buy	+424	New	+$490	﹤0.01%	1404

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Rise Advisors's PACB Position: Q4 2025 in Review

Rise Advisors sold out of Pacific Biosciences (PACB) in Q4 2025, closing a stake of 424 shares — an estimated $543 sold.

Rise Advisors first reported a position in PACB in Q2 2025 and held it in 2 quarters. The position peaked at $543 in Q3 2025. 215 funds tracked by Wall St. Rank hold PACB as of Q4 2025.

Rise Advisors reported no remaining Pacific Biosciences position as of Q4 2025 after selling out during the quarter.
Rise Advisors sold 424 Pacific Biosciences shares in Q4 2025, an estimated $543.
Rise Advisors first reported a position in Pacific Biosciences in Q2 2025 and held it in 2 quarters.
Rise Advisors's Pacific Biosciences position peaked at $543 in Q3 2025.
215 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.